Biofrontera Inc. Announces Preliminary Product Revenues for the Third Quarter of 2022
October 05, 2022 17:00 ET
|
Biofrontera Inc.
WOBURN, Mass., Oct. 05, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, today announced...
Biofrontera Inc. to Present at the Roth Inaugural Healthcare Opportunities Conference
September 29, 2022 10:04 ET
|
Biofrontera Inc.
WOBURN, Mass., Sept. 29, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announced today that...
Biofrontera Inc.’s Marketing Campaign and Website for Ameluz Won 2022 PM360 Trailblazer Awards
September 26, 2022 08:30 ET
|
Biofrontera Inc.
WOBURN, Mass., Sept. 26, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announced today that...
Biofrontera Inc. Names Gerard DiGirolamo as National Sales Director
September 13, 2022 08:30 ET
|
Biofrontera Inc.
WOBURN, Mass., Sept. 13, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announces the...
Biofrontera Inc. Announces Notice of Allowance for Nanoemulsion Composition-of-Matter U.S. Patent
September 06, 2022 10:31 ET
|
Biofrontera Inc.
Company also granted special designation that enables expedited review of a recent U.S. patent application relating to novel PDT illumination protocols WOBURN, Mass., Sept. 06, 2022 (GLOBE...
Biofrontera Inc.’s Leslie Hopkins Named PM360 Trailblazer 2022 Brand Champion for Dermatology
August 18, 2022 11:05 ET
|
Biofrontera Inc.
WOBURN, Mass., Aug. 18, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announced today that...
Biofrontera Inc. Reports Second Quarter 2022 Financial Results and Provides a Business Update
August 12, 2022 08:33 ET
|
Biofrontera Inc.
Conference call begins at 11:00 a.m. Eastern time today WOBURN, Mass., Aug. 12, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the...
Biofrontera Inc. to Report Second Quarter Financial Results on August 12, 2022
August 04, 2022 08:30 ET
|
Biofrontera Inc.
WOBURN, Mass., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announces it will...
Biofrontera Inc. Announces Patent in Australia for Novel Illumination Protocols Granted to Biofrontera Bioscience GmbH
August 01, 2022 11:00 ET
|
Biofrontera Inc.
Patent Improves Differentiated Profile of Ameluz-PDT by Expected Reduced Pain Intensity while Maintaining Efficacy WOBURN, Mass., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI),...
Biofrontera Inc. Announces Exercise of Existing Warrants and Issuance of Warrants in Private Placement
July 27, 2022 08:45 ET
|
Biofrontera Inc.
WOBURN, Mass., July 27, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announced today it has...